Heart failure & cardiomyopathiesRandomised controlled trial
Short- and Mid-Term Effects of Empagliflozin on Sodium Balance and Fluid Regulation in Chronic Heart Failure
- Randomised controlled trial
- placebo-controlled
- 2:1 randomisation
Authors' conclusion
Mid-range effects of empagliflozin in heart failure with reduced EF include transient natriuresis and sustained glucosuria, with compensatory reductions in FWC. Reductions in skin sodium content were maintained, and volume homeostasis in CHF patients stabilized after 3 months.
Study context
- Population
- Patients with NYHA class II–III chronic HF and ejection fraction (EF) ≤49%
- Participants
- 74 patients
- Comparison
- Empagliflozin 10 mg vs placebo
- Empagliflozinn = 48
- Placebon = 26reference
Primary result
As reported in the abstract
Natriuresis (24-h urine sodium excretion), empagliflozin vs placebo · 1 and 3 months
Empagliflozin significantly increased natriuresis at 1 month
p = 0.040
Original publication
Short- and Mid-Term Effects of Empagliflozin on Sodium Balance and Fluid Regulation in Chronic Heart Failure. Eur J Heart Fail. Published 4 November 2025. doi:10.1002/ejhf.70078
Summarised from the published abstract; every number is checked against it